Urine-derived stem cells in kidney disease: progress, challenges, and future directions

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Chronic kidney disease (CKD) is a major global health burden with limited treatment options that address the underlying causes of fibrosis or promote regeneration. Urine-derived stem cells (USCs) have emerged as a promising tool in regenerative nephrology, offering a non-invasive and accessible source of multipotent cells with therapeutic potential. Sharing key properties with mesenchymal stem cells, USCs demonstrate paracrine activity, immunomodulation, and efficient extracellular vesicle (EV) production, and have shown anti-fibrotic, anti-inflammatory, and pro-regenerative effects in preclinical models of acute and chronic kidney injury. Recent advances in biomaterials and delivery technologies, including scaffold-free cell sheets and engineered EVs, have further enhanced the potential of USC-based therapies. However, challenges remain, particularly regarding functional integration, delivery optimization, and donor variability. This review summarizes the current progress in USC-based kidney therapy, identifies key limitations, and outlines future directions to support the translation of USC-based interventions into clinical practice.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.